Brought to you by

Novartis buys Genoptix for $440mm; Genoptix sold off
26 Oct 2018
Executive Summary
Novartis AG has agreed to buy publicly traded Genoptix Inc. (laboratory testing) for $440mm in cash, or $25 for each share (a 25% premium).
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com